Guidance
6 Related NICE guidance
Published
-
Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of ovarian cancer. NICE technology appraisal guidance 284 (2013).
-
Ovarian cancer: the recognition and initial management of ovarian cancer. NICE clinical guideline 122 (2011).
-
Trabectedin for the treatment of relapsed ovarian cancer. NICE technology appraisal guidance 222 (2011).
-
Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer: review of technology appraisal guidance 28, 45 and 55. NICE technology appraisal guidance 91 (2005).
-
Guidance on the use of paclitaxel in the treatment of ovarian cancer. NICE technology appraisal guidance 55 (2003).
Under development
NICE is developing the following guidance (details available from www.nice.org.uk):
-
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced ovarian cancer (for recurrent disease only) (review of technology appraisal guidance 91 and 222). NICE technology appraisal guidance. Publication expected February 2014.
-
Vintafolide in combination with pegylated liposomal doxorubicin hydrochloride for the treatment of folate receptor positive, platinum-resistant ovarian cancer. NICE technology appraisal guidance. Publication expected July 2014.